Acadian Asset Management LLC Grows Position in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Acadian Asset Management LLC significantly increased its stake in Kiniksa Pharmaceuticals International by 170.3% during the first quarter, owning over 1 million shares valued at approximately $22.9 million.
• Several other institutional investors have also enhanced their positions, with 53.95% of Kiniksa's stock now held by institutional investors.
• Wall Street analysts have raised their target prices for Kiniksa Pharmaceuticals, with Wells Fargo setting a new target of $42.00 and Jefferies Financial Group increasing theirs to $54.00, contributing to an overall "Buy" rating for the stock.

Acadian Asset Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 170.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,034,321 shares of the company's stock after purchasing an additional 651,700 shares during the quarter. Acadian Asset Management LLC owned about 1.42% of Kiniksa Pharmaceuticals International worth $22,961,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $301,000. GAMMA Investing LLC boosted its position in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. Deutsche Bank AG boosted its position in Kiniksa Pharmaceuticals International by 177.1% during the first quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after purchasing an additional 252,125 shares during the period. Victory Capital Management Inc. bought a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $1,184,000. Finally, Nuveen Asset Management LLC boosted its position in Kiniksa Pharmaceuticals International by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. Institutional investors own 53.95% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on KNSA shares. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Trading Down 1.7%

Shares of Kiniksa Pharmaceuticals International stock opened at $36.23 on Thursday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $37.25. The company has a market cap of $2.69 billion, a price-to-earnings ratio of 905.98 and a beta of 0.20. The company's 50-day moving average price is $31.49 and its 200-day moving average price is $26.84.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 11,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total value of $383,240.00. Following the sale, the chief accounting officer directly owned 38,011 shares of the company's stock, valued at $1,324,303.24. This trade represents a 22.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Thomas Malley sold 78,233 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 562,271 shares of company stock valued at $18,716,309 over the last three months. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.